Balyasny Asset Management L.P.
Overview
Balyasny Asset Management is a global multi-strategy investment firm that invests across strategies including equities long/short, fixed income, macro, commodities, and systematic trading.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oak Hill Bio | Jun 2026 | Series A | Lead |
| Coultreon Biopharma | Apr 2026 | Series A | Co-investor |
| Obsidian Therapeutics | Apr 2026 | Private Placement | Co-investor |
| Faeth Therapeutics | Feb 2026 | Private Placement | Co-investor |
| TRexBio | Jan 2026 | Series B Extension | Lead |
Key People
Taylor O'Malley
Co-Founder President
Wei Jie Tan
Managing Director, Portfolio Manager
David Levary
Partner, Portfolio Manager
Dmitry Balyasny
Managing Partner Chief Investment Officer
Adam Schwartz
Portfolio Manager
Amol Pai
Portfolio Manager
Anish Abuwala
Portfolio Manager
Anthony DePalo
Portfolio Manager
Anthony Inguaggiato
Portfolio Manager
Ari Ades
Portfolio Manager
Ben Cahill
Portfolio Manager
Boris Mangal
Portfolio Manager
Brian VanLeeuwen
Portfolio Manager
Charles Sweat
Portfolio Manager
Chintan Mehta
Portfolio Manager
Daan Ridder Everts
Portfolio Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.